MicroRNA signature and cardiovascular dysfunction

Journal of Cardiovascular Pharmacology

Volumn 65, Issue 5, 2015, Pages 419-429

  Arunachalam, Gnanapragasam ^a   Upadhyay, Rohit ^a   Ding, Hong ^a   Triggle, Chris R ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (Qatar)

Author keywords

cardiovascular disease; diabetes; endothelial cells; endothelial dysfunction; endothelial progenitor cell; microRNA; vascular disease

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; METFORMIN; MICRORNA; GENETIC MARKER;

3' UNTRANSLATED REGION; ANGIOGENESIS; ARTICLE; BIOGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG TARGETING; EARLY DIAGNOSIS; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GENE EXPRESSION; GENE REPRESSION; GENETIC TRANSCRIPTION; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; INFLAMMATION; MICROANGIOPATHY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REGULATORY MECHANISM; SENESCENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSLATION REGULATION; VASCULAR DISEASE; ANIMAL; CARDIOVASCULAR DISEASES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETICS; METABOLISM; PREDICTIVE VALUE; PROGNOSIS;

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC MARKERS; HUMANS; MICRORNAS; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84930272738     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000178     Document Type: Article

References (161)

1. Owens AT, Jessup M. The year in heart failure. J Am Coll Cardiol. 2012;60:359-368.
2. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058-1070.
3. Quiat D, Olson EN. MicroRNAs in cardiovascular disease: From pathogenesis to prevention and treatment. J Clin Invest. 2013;123:11-18.
4. Gurha P, Marian AJ. Noncoding RNAs in cardiovascular biology and disease. Circ Res. 2013;113:e115-e120.
5. Cordes KR, Srivastava D. MicroRNA regulation of cardiovascular development. Circ Res. 2009;104:724-732.
6. Hata A. Functions of microRNAs in cardiovascular biology and disease. Annu Rev Physiol. 2013;75:69-93.
7. Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. Nature. 2011;469:336-342.
8. Van Rooij E. The art of microRNA research. Circ Res. 2011;108: 219-234.
9. Small EM, Frost RJ, Olson EN. MicroRNAs add a new dimension to cardiovascular disease. Circulation. 2010;121:1022-1032.
10. Zampetaki A, Mayr M. MicroRNAs in vascular and metabolic disease. Circ Res. 2012;110:508-522.
11. Olson EN. MicroRNAs as therapeutic targets and biomarkers of cardiovascular disease. Sci Transl Med. 2014;6:239ps3.
12. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843-854.
13. Reinhart BJ. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000;403:101-106.
14. Kozomara A, Griffiths-Jones S. miRBase: Annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014;42: D68-D73.
15. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of posttranscriptional regulation by microRNAs: Are the answers in sight? Nat Rev Genet. 2008;9:102-114.
16. Bauersachs J, Thum T. Biogenesis and regulation of cardiovascular microRNAs. Circ Res. 2011;109:334-347.
17. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11: 597-610.
18. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-297.
19. Vickers KC, Rye KA, Tabet F. MicroRNAs in the onset and development of cardiovascular disease. Clin Sci (Lond). 2014;126:183-194.
20. Mann DL. MicroRNAs and the failing heart. N Engl J Med. 2007;356: 2644-2645.
21. Srivastava D, Heidersbach AJ. Small solutions to big problems: Micro-RNAs for cardiac regeneration. Circ Res. 2013;112:1412-1414.
22. Davis-Dusenbery BN, Hata A. Mechanisms of control of microRNA biogenesis. J Biochem. 2010;148:381-392.
23. Siomi H, Siomi MC. Posttranscriptional regulation of microRNA biogenesis in animals. Mol Cell. 2010;38:323-332.
24. Zhang C. MicroRNA: Role in cardiovascular biology and disease. Clin Sci (Lond). 2008;114:699-706.
25. Melman YF, Shah R, Das S. MicroRNAs in heart failure: Is the picture becoming less mirky? Circ Heart Fail. 2014;7:203-214.
26. Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature. 2005;436:214-220.
27. Sayed D, Abdellatif M. MicroRNAs in development and disease. Physiol Rev. 2011;91:827-887.
28. Park CY, Choi YS, McManus MT. Analysis of microRNA knockouts in mice. Hum Mol Genet. 2010;19:R169-R175.
29. Saxena A, Tabin CJ. MiRNA-processing enzyme dicer is necessary for cardiac outflow tract alignment and chamber septation. Proc Natl Acad Sci U S A. 2010;107:87-91.
30. Huang ZP, Chen JF, Regan JN, et al. Loss of microRNAs in neural crest leads to cardiovascular syndromes resembling human congenital heart defects. Arterioscler Thromb Vasc Biol. 2010;30:2575-2586.
31. da Costa Martins PA, Bourajjaj M, Gladka M, et al. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation. 2008;118:1567-1576.
32. Rao PK, Toyama Y, Chiang HR, et al. Loss of cardiac microRNAmediated regulation leads to dilated cardiomyopathy and heart failure. Circ Res. 2009;105:585-594.
33. Yang WJ, Yang DD, Na S, et al. Dicer is required for embryonic angiogenesis during mouse development. J Biol Chem. 2005;280:9330-9335.
34. Chen JF, Mandel EM, Thomson JM, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet. 2006;38:228-233.
35. Chinchilla A, Lozano E, Daimi H, et al. MicroRNA profiling during mouse ventricular maturation: A role for miR-27 modulating Mef2c expression. Cardiovasc Res. 2011;89:98-108.
36. Zhao Y, Ransom JF, Li A, et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell. 2007;129: 303-317.
37. Van Rooij E, Quiat D, Johnson BA, et al. A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev Cell. 2009;17:662-673.
38. Porrello ER, Johnson BA, Aurora AB, et al. MiR-15 family regulates postnatal mitotic arrest of cardiomyocytes. Circ Res. 2011;109:670-679.
39. Hullinger TG, Montgomery RL, Seto AG, et al. Inhibition of miR-15 protects against cardiac ischemic injury. Circ Res. 2012;110:71-81.
40. Ventura A, Young AG, Winslow MM, et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell. 2008;132:875-886.
41. Elia L, Quintavalle M, Zhang J, et al. The knockout of miR-143 and-145 alters smooth muscle cell maintenance and vascular homeostasis in mice: Correlates with human disease. Cell Death Differ. 2009;16:1590-1598.
42. Xin M, Small EM, Sutherland LB, et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev. 2009;23:2166-2178.
43. Fiedler J, Thum T. MicroRNAs in myocardial infarction. Arterioscler Thromb Vasc Biol. 2013;33:201-205.
44. Kumarswamy R, Lyon AR, Volkmann I, et al. SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt/FoxO3Adependent pathway. Eur Heart J. 2012;33:1067-1075.
45. Karakikes I, Chaanine AH, Kang S, et al. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc. 2013;23:e000078.
46. Yang B, Lin H, Xiao J, et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med. 2007;13:486-491.
47. Lu Y, Zhang Y, Shan H, et al. MicroRNA-1 downregulation by propranolol in a rat model of myocardial infarction: A new mechanism for ischaemic cardioprotection. Cardiovasc Res. 2009;84:434-441.
48. Shan ZX, Lin QX, Fu YH, et al. Upregulated expression of miR-1/miR-206 in a rat model of myocardial infarction. Biochem Biophys Res Commun. 2009;381:597-560.
49. Ai J, Zhang R, Li Y, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun. 2010;391:73-77.
50. Danowski N, Manthey I, Jakob HG, et al. Decreased expression of miR-133a but not of miR-1 is associated with signs of heart failure in patients undergoing coronary bypass surgery. Cardiology. 2013;125:125-130.
51. Van Rooij E, Sutherland LB, Thatcher JE, et al. Dysregulation of micro-RNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A. 2008;105:13027-13032.
52. Ye Y, Hu Z, Lin Y, et al. Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury. Cardiovasc Res. 2010;87:535-544.
53. Fiedler J, Jazbutyte V, Kirchmaier BC, et al. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation. 2011;124:720-730.
54. Wang J, Huang W, Xu R, et al. MicroRNA-24 regulates cardiac fibrosis after myocardial infarction. J Cell Mol Med. 2012;16:2150-2160.
55. Qian L, Van Laake LW, Huang Y, et al. MiR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes. J Exp Med. 2011;208: 549-560.
56. Pan Z, Sun X, Shan H, et al. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-b1 pathway. Circulation. 2012;126:840-850.
57. Aurora AB, Mahmoud AI, Luo X, et al. MicroRNA-214 protects the mouse heart from ischemic injury by controlling Ca(2)(+) overload and cell death. J Clin Invest. 2012;122:1222-1232.
58. Wang JX, Jiao JQ, Li Q, et al. MiR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nat Med. 2011;17:71-78.
59. Boon RA, Iekushi K, Lechner S, et al. MicroRNA-34a regulates cardiac ageing and function. Nature. 2013;495:107-110.
60. Da Costa Martins PA, De Windt LJ. MicRNAs in control of cardiac hypertrophy. Cardiovasc Res. 2012;93:563-572.
61. Li Q, Song XW, Zou J, et al. Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twinfilin-1 to provoke cardiac hypertrophy. J Cell Sci. 2010;123:2444-2452.
62. Elia L, Contu R, Quintavalle M, et al. Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation. 2009;120:2377-2385.
63. Ikeda S, He A, Kong SW, et al. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol. 2009;29:2193-2204.
64. Liu N, Bezprozvannaya S, Williams AH, et al. MicroRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev. 2008;22:3242-3254.
65. Dong DL, Chen C, Huo R, et al. Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: A novel mechanism for progressive cardiac hypertrophy. Hypertension. 2010; 55:946-952.
66. Wang K, Long B, Zhou J, et al. MiR-9 and NFATc3 regulate myocardin in cardiac hypertrophy. J Biol Chem. 2010;285:11903-11912.
67. Yang Y, Ago T, Zhai P, et al. Thioredoxin 1 negatively regulates angiotensin ii-induced cardiac hypertrophy through upregulation of miR-98/let-7. Circ Res. 2011;108:305-313.
68. Van Rooij E, Sutherland LB, Liu N, et al. A signature pattern of stressresponsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A. 2006;103:18255-18260.
69. Callis TE, Pandya K, Seok HY, et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest. 2009;119: 2772-2786.
70. Alcendor RR, Kirshenbaum LA, Imai S, et al. Silent information regulator 2alpha, a longevity factor and class III histone deacetylase, is an essential endogenous apoptosis inhibitor in cardiac myocytes. Circ Res. 2004;95:971-980.
71. Rane S, He M, Sayed D, et al. An antagonism between the Akt and beta-adrenergic signaling pathways mediated through their reciprocal effects on miR-199a-5p. Cell Signal. 2010;22:1054-1062.
72. Tatsuguchi M, Seok HY, Callis TE, et al. Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol. 2007;42:1137-1141.
73. Thum T, Lorenzen JM. Cardiac fibrosis revisited by microRNA therapeutics. Circulation. 2012;126:800-802.
74. Van Rooij E, Olson EN. Searching for miR-acles in cardiac fibrosis. Circ Res. 2009;104:138-140.
75. Roncarati R, Viviani Anselmi C, Losi MA, et al. Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2014;63:920-927.
76. Akat KM, Moore-McGriff D, Morozov P, et al. Comparative RNAsequencing analysis of myocardial and circulating small RNAs in human heart failure and their utility as biomarkers. Proc Natl Acad Sci U S A. 2014;111:11151-11156. http://www.ncbi.nlm.nih.gov/ pubmed/25012294.
77. Shaik S, Wang Z, Inuzuka H, et al. Endothelium aging and vascular diseases. In: Wang Z, Inuzuka H, eds. Senescence and Senescencerelated Disorders. Rijeka, Croatia: InTech; 2013:3-21.
78. Triggle CR, Samuel SM, Ravishankar S, et al. The endothelium: Influencing vascular smooth muscle in many ways. Can J Physiol Pharmacol. 2012;90:713-738.
79. Staszel T, Zapala B, Polus A, et al. Role of microRNAs in endothelial cell pathophysiology. Pol Arch Med Wewn. 2011;121:361-366.
80. Yamakuchi M. MicroRNAs in vascular biology. Int J Vasc Med. 2012; 2012:794-898.
81. Ito T, Yagi S, Yamakuchi M. MicroRNA-34a regulation of endothelial senescence. Biochem Biophys Res Commun. 2010;398:735-740.
82. Zhao T, Li J, Chen AF. MicroRNA-34a induces endothelial progenitor cell senescence and impedes its angiogenesis via suppressing silent information regulator 1. Am Physiol Endocrinol Metab. 2010;299:E110-E116.
83. Menghini R, Casagrande V, Cardellini M, et al. MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. Circulation. 2009;120:1524-1532.
84. Magenta A, Cencioni C, Fasanaro P, et al. MiR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition. Cell Death Differ. 2011;18:1628-1639.
85. Vasa-Nicotera M, Chen H, Tucci P, et al. MiR-146a is modulated in human endothelial cell with aging. Atherosclerosis. 2011;217:326-330.
86. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005; 438:932-936.
87. Suarez Y, Sessa WC. MicroRNAs as novel regulators of angiogenesis. Circ Res. 2009;104:442-454.
88. Wang S, Aurora AB, Johnson BA, et al. The endothelial-specific micro-RNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008;15:261-271.
89. Fish JE, Santoro MM, Morton SU, et al. MiR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 2008;15:272-284.
90. Nicoli S, Standley C, Walker P, et al. MicroRNA-mediated integration of haemodynamics and VEGF signalling during angiogenesis. Nature. 2010;464:1196-1200.
91. Sessa R, Seano G, di Blasio L, et al. The miR-126 regulates angiopoietin-1 signaling and vessel maturation by targeting p85b. Biochim Biophys Acta. 2012;1823:1925-1935.
92. Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010;107:810-817.
93. Meng S, Cao JT, Zhang B, et al. Downregulation of microRNA-126 in endothelial progenitor cells from diabetes patients, impairs their functional properties, via target gene spred-1. J Mol Cell Cardiol. 2012;53:64-72.
94. Poliseno L, Tuccoli A, Mariani L, et al. MicroRNAs modulate the angiogenic properties of HUVECs. Blood. 2006;108:3068-3071.
95. Suarez Y, Fernandez-Hernando C, Pober JS, et al. Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res. 2007;100:1164-1173.
96. Dentelli P, Rosso A, Orso F, et al. MicroRNA-222 controls neovascularization by regulating signal transducer and activator of transcription 5a expression. Arterioscler Thromb Vasc Biol. 2010;30:1562-1568.
97. Chen Y, Banda M, Speyer L, et al. Regulation of the expression and activity of the antiangiogenic homeobox gene GAX/MEOX2 by ZEB2 and microRNA-221. Mol Cell Biol. 2010;30:3902-3913.
98. Bonauer A, Carmona G, Iwasaki M, et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science. 2009;324:1710-1713.
99. Doebele C, Bonauer A, Fischer A, et al. Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. Blood. 2010;115:4944-4950.
100. Zhou Q, Gallagher R, Ufret-Vincenty R, et al. Regulation of angiogenesis and choroidal neovascularization by members of microRNA-23;27;24 clusters. Proc Natl Acad Sci U S A. 2011;108:8287-8292.
101. Chamorro-Jorganes A, Araldi E, Penalva LO, et al. MicroRNA-16 and microRNA-424 regulate cell-autonomous angiogenic functions in endothelial cells via targeting vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1. Arterioscler Thromb Vasc Biol. 2011;31:2595-2606.
102. Smits M, Mir SE, Nilsson RJ, et al. Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2. PLoS One. 2011;6:e16282.
103. Chan YC, Khanna S, Roy S, et al. MiR-200b targets Ets-1 and is downregulated by hypoxia to induce angiogenic response of endothelial cells. J Biol Chem. 2011;286:2047-2056.
104. Chen Y, Gorski DH. Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood. 2008;111:1217-1226.
105. Wurdinger T, Tannous BA, Saydam O, et al. MiR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell. 2008;14:382-393.
106. Anand S, Majeti BK, Acevedo LM, et al. Microrna-132-mediated loss of PDGFRbeta/B-RAF activates the endothelium to facilitate pathological angiogenesis. Nat Med. 2010;16:909-914.
107. Fasanaro P, D'Alessandra Y, Di Stefano V, et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem. 2008;283:15878-15883.
108. Harris TA, Yamakuchi M, Ferlito M, et al. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U.S.A. 2008;105:1516-1521.
109. Ji R, Cheng Y, Yue J, et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of microRNA in vascular neointimal lesion formation. Circ Res. 2007;100:1579-1588.
110. Santulli G, Wronska A, Uryu K, et al. A selective microRNA-based strategy inhibits restenosis while preserving endothelial function. J Clin Invest. 2014;124:4102-4114.
111. Sun X, Icli B, Wara AK, et al. MicroRNA-181b regulates NF-kB-mediated vascular inflammation. J Clin Invest. 2012;122:1973-1990.
112. Fang Y, Shi C, Manduchi E, et al. MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro. Proc Natl Acad Sci U S A. 2010;107:13450-13455.
113. Suarez Y, Wang C, Manes TD, et al. Cutting edge: TNF-induced micro-RNAs regulate TNF-induced expression of E-selectin and intercellular adhesion molecule-1 on human endothelial cells: Feedback control of inflammation. J Immunol. 2010;184:21-25.
114. Martin MM, Lee EJ, Buckenberger JA, et al. MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. J Biol Chem. 2006;281:18277-18284.
115. O'Connell RM, Rao DS, Chaudhuri AA, et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med. 2008;205:585-594.
116. Urbich C, Kuehbacher A, Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res. 2008;79: 581-588.
117. Wang XH, Qian RZ, Zhang W, et al. MicroRNA-320 expression in myocardial microvascular endothelial cells and its relationship with insulin-like growth factor-1 in type 2 diabetic rats. Clin Exp Pharmacol Physiol. 2009;36:181-188.
118. Li Y, Song YH, Li F, et al. MicroRNA-221 regulates high glucoseinduced endothelial dysfunction. Biochem Biophys Res Commun. 2009; 381:81-83.
119. Togliatto G, Trombetta A, Dentelli P, et al. MiR221/miR222-driven post-transcriptional regulation of P27KIP1 and P57KIP2 is crucial for high-glucose-and AGE-mediated vascular cell damage. Diabetologia. 2011;54:1930-1940.
120. Villeneuve LM, Kato M, Reddy MA, et al. Enhanced levels of microRNA-125b in vascular smooth muscle cells of diabetic db/db mice lead to increased inflammatory gene expression by targeting the histone methyltransferase Suv39h1. Diabetes. 2010;59:2904-2915.
121. Caporali A, Meloni M, Vollenkle C, et al. Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation. 2011;123:282-291.
122. Care A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med. 2007;13:613-618.
123. Feng B, Chen S, George B, et al. MiR133a regulates cardiomyocyte hypertrophy in diabetes. Diabetes Metab Res Rev. 2010;26:40-49.
124. Xiao J, Luo X, Lin H, et al. MicroRNA mir-133 represses HERG K+ channel expression contributing to qt prolongation in diabetic hearts. J Biol Chem. 2007;282:12363-12367.
125. Shan ZX, Lin QX, Deng CY, et al. MiR-1/miR-206 regulate Hsp60 expression contributing to glucose-mediated apoptosis in cardiomyocytes. FEBS Lett. 2010;584:3592-3600.
126. Yu XY, Song YH, Geng YJ, et al. Glucose induces apoptosis of cardiomyocytes via microRNA-1 and IGF-1. Biochem Biophys Res Commun. 2008;376:548-552.
127. Katare R, Caporali A, Zentilin L, et al. Intravenous gene therapy with PIM-1 via a cardiotropic viral vector halts the progression of diabetic cardiomyopathy through promotion of prosurvival signaling. Circ Res. 2011;108:1238-1251.
128. Natarajan R, Putta S, Kato M. MicroRNAs and diabetic complications. J Cardiovasc Transl Res. 2012;5:413-422.
129. Li R, Chung AC, Yu X, et al. MicroRNAs in diabetic kidney disease. Int J Endocrinol. 2014;2014:593956.
130. Kato M, Zhang J, Wang M, et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A. 2007;104:3432-3437.
131. Krupa R, Jenkins D, DongLuo A, et al. Loss of microRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol. 2010; 21;438-447.
132. Kato M, Putta S, Wang M, et al. TGF-beta 1 activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol. 2009;11:881-889.
133. Kato M, Wang L, Putta S, et al. Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of mir-216a, mediates TGF-beta-induced collagen expression in kidney cells. J Biol Chem. 2010;285:34004-34015.
134. Kato M, Arce L, Wang M, et al. A microRNA circuit mediates transforming growth factor-b1 autoregulation in renal glomerular mesangial cells. Kidney Int. 2011;80:358-368.
135. Wang Q, Wang Y, Minto AW, et al. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J. 2008;22:4126-4135.
136. Long J, Wang Y, Wang W, et al. Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions. J Biol Chem. 2010;285:23457-23465.
137. Wang B, Komers R, Carew R, et al. Suppression of microRNA-29 expression by TGF-beta1 promotes collagen expression and renal fibrosis. J Am Soc Nephrol. 2012;23:252-265.
138. Long J, Wang Y, Wang W, et al. MicroRNA-29c is a signature micro-RNA under high glucose conditions that targets sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy. J Biol Chem. 2011;286:11837-11848.
139. Kovacs B, Lumayag S, Cowan C, et al. MicroRNAs in early diabetic retinopathy in streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci. 2011;52:4402-4409.
140. McArthur K, Feng B, Wu Y, et al. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes. 2011;60:1314-1323.
141. Silva VA, Polesskaya A, Sousa TA, et al. Expression and cellular localization of microRNA-29b and RAX, an activator of the RNA-dependent protein kinase (PKR), in the retina of streptozotocininduced diabetic rats. Mol Vis. 2011;17:2228-2240.
142. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513-10518.
143. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141:672-675.
144. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997-1006.
145. Zernecke A, Bidzhekov K, Noels H, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal. 2009;2:ra81.
146. Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654-659.
147. Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2001;108:5003-5008.
148. Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011;13:423-433.
149. Zhang Y, Liu D, Chen X, et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell. 2010;39:133-144.
150. Hulsmans M, Holvoet P. MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease. Cardiovasc Res. 2013;100:7-18.
151. Hulsmans M, Holvoet P. MicroRNAs as early biomarkers in obesity and related metabolic and cardiovascular diseases. Curr Pharm Des. 2013;19:5704-5717.
152. Van Rooij E, Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO Mol Med. 2014;6:851-864.
153. Van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: Opportunities and obstacles. Nat Rev Drug Discov. 2012;11:860-872.
154. Dangwal S, Thum T. MicroRNA therapeutics in cardiovascular disease models. Annu Rev Pharmacol Toxicol. 2014;54:185-203.
155. Hermeking H. MicroRNAs in the p53 network: Micromanagement of tumour suppression. Nat Rev Cancer. 2012;12:613-626.
156. Blandino G, Valerio M, Cioce M, et al. Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. Nat Commun. 2012;3:865.
157. Bao B, Wang Z, Ali S, et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila). 2012;5:355-364.
158. Triggle CR, Arunachalam G, Upadhyay R, et al. Metformin: Targets SIRT1 and microRNAs in microvascular endothelial cells. J Vasc Res. 2014;51(suppl 1):37 (abstract
159. Arunachalam G, Samuel SM, Marei I, et al. Micro RNA-34a mediates impaired angiogenesis in diabetes: Role of SIRT1 and Metformin. FASEB J. 2014;28:1051.2 (abstract
160. Arunachalam G, Samuel SM, Marei I, et al. Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1. Br J Pharmacol. 2014;171:523-535.
161. Martin-Montalvo A, Mercken EM, Mitchell SJ, et al. Metformin improves healthspan and lifespan in mice. Nat Commun. 2013;4:2192.